IMREG's IMREG-1 TREATMENT IND REQUEST DENIED BY FDA
IMREG's IMREG-1 TREATMENT IND REQUEST DENIED BY FDA, the company announced May 5. Imreg said it would meet with FDA "in the near future" to discuss the protocol for a study required to demonstrate whether Imreg-1 is safe and effective. Once Imreg and FDA agree on a protocol and initiate further testing, a second Treatment IND application may be filed. Imreg's press statement declares: "Approval of a request for a Treatment protocol requires that the drug be under investigation in a controlled clinical trial, or that all necessary clinical trials have been completed." The application has been on clinical hold since last November. The Treatment IND regulations stipulate that FDA must approve or disapprove a request within 30 days. The agency placed the clinical hold on the application after referring the issues involved to an advisory committee and realizing that a recommendation would not be forthcoming within the 30-day limit. Submitted on Oct. 5, Imreg's Treatment IND request was discussed at an inconclusive meeting of FDA's Vaccines & Related Biological Products Advisory Committee on Nov. 18 and placed on clinical hold pending review of the supporting data at a second meeting of the panel. At its second meeting on Imreg-1, the committee concluded that the data indicated the biologic may be effective in controlling ARC (AIDS-related complex) but must be corroborated by further testing ("The Pink Sheet" April 10, T&G-1).
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth